With the number of rare diseases still outnumbering treatments, pharmaceutical companies are continuing to take advantage of regulatory incentives to develop new drugs for these patient populations. Orphan drug incentives available in the US and Europe are therefore of continuing interest. This meeting will discuss the orphan drug market and opportunities for new research. The orphan drug market is expected to reach $176 billion by 2020.
